SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lagergren M.)
 

Sökning: WFRF:(Lagergren M.) > (2015-2019) > Immune activation b...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006102naa a2201477 4500
001oai:prod.swepub.kib.ki.se:142430259
003SwePub
008240818s2019 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1424302592 URI
024a https://doi.org/10.1136/gutjnl-2018-3176242 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Turkington, RC4 aut
2451 0a Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
264 c 2019-03-09
264 1b BMJ,c 2019
520 a Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response following neoadjuvant chemotherapy in OAC.DesignTranscriptional profiling of 273 formalin-fixed paraffin-embedded prechemotherapy endoscopic OAC biopsies was performed. All patients were treated with platinum-based neoadjuvant chemotherapy and resection between 2003 and 2014 at four centres in the Oesophageal Cancer Clinical and Molecular Stratification consortium. CD8 and programmed death ligand 1 (PD-L1) immunohistochemical staining was assessed in matched resection specimens from 126 cases. Kaplan-Meier and Cox proportional hazards regression analysis were applied according to DDIR status for recurrence-free survival (RFS) and overall survival (OS).ResultsA total of 66 OAC samples (24%) were DDIR positive with the remaining 207 samples (76%) being DDIR negative. DDIR assay positivity was associated with improved RFS (HR: 0.61; 95% CI 0.38 to 0.98; p=0.042) and OS (HR: 0.52; 95% CI 0.31 to 0.88; p=0.015) following multivariate analysis. DDIR-positive patients had a higher pathological response rate (p=0.033), lower nodal burden (p=0.026) and reduced circumferential margin involvement (p=0.007). No difference in OS was observed according to DDIR status in an independent surgery-alone dataset.DDIR-positive OAC tumours were also associated with the presence of CD8+ lymphocytes (intratumoural: p<0.001; stromal: p=0.026) as well as PD-L1 expression (intratumoural: p=0.047; stromal: p=0.025).ConclusionThe DDIR assay is strongly predictive of benefit from DNA-damaging neoadjuvant chemotherapy followed by surgical resection and is associated with a proinflammatory microenvironment in OAC.
700a Knight, LA4 aut
700a Blayney, JK4 aut
700a Secrier, M4 aut
700a Douglas, R4 aut
700a Parkes, EE4 aut
700a Sutton, EK4 aut
700a Stevenson, L4 aut
700a McManus, D4 aut
700a Halliday, S4 aut
700a McCavigan, AM4 aut
700a Logan, GE4 aut
700a Walker, SM4 aut
700a Steele, CJ4 aut
700a Perner, J4 aut
700a Bornschein, J4 aut
700a MacRae, S4 aut
700a Miremadi, A4 aut
700a McCarron, E4 aut
700a McQuaid, S4 aut
700a Arthur, K4 aut
700a James, JA4 aut
700a Eatock, MM4 aut
700a O'Neill, R4 aut
700a Noble, F4 aut
700a Underwood, TJ4 aut
700a Harkin, DP4 aut
700a Salto-Tellez, M4 aut
700a Fitzgerald, RC4 aut
700a Kennedy, RD4 aut
700a Noorani, A4 aut
700a Edwards, PAW4 aut
700a Grehan, N4 aut
700a Nutzinger, B4 aut
700a Hughes, C4 aut
700a Fidziukiewicz, E4 aut
700a Crawte, J4 aut
700a Northrop, A4 aut
700a Contino, G4 aut
700a Li, XD4 aut
700a de la Rue, R4 aut
700a O'Donovan, M4 aut
700a Malhotra, S4 aut
700a Tripathi, M4 aut
700a Tavare, S4 aut
700a Lynch, AG4 aut
700a Eldridge, M4 aut
700a Bower, L4 aut
700a Devonshire, G4 aut
700a Jammula, S4 aut
700a Davies, J4 aut
700a Crichton, C4 aut
700a Carroll, N4 aut
700a Safranek, P4 aut
700a Hindmarsh, A4 aut
700a Sujendran, V4 aut
700a Hayes, SJ4 aut
700a Ang, Y4 aut
700a Preston, SR4 aut
700a Oakes, S4 aut
700a Bagwan, I4 aut
700a Save, V4 aut
700a Skipworth, RJE4 aut
700a Hupp, TR4 aut
700a Tucker, O4 aut
700a Beggs, A4 aut
700a Taniere, P4 aut
700a Puig, S4 aut
700a Owsley, J4 aut
700a Barr, H4 aut
700a Shepherd, N4 aut
700a Old, O4 aut
700a Lagergren, Ju Karolinska Institutet4 aut
700a Gossage, J4 aut
700a Davies, A4 aut
700a Chang, FJ4 aut
700a Zylstra, J4 aut
700a Mahadeva, U4 aut
700a Goh, V4 aut
700a Ciccarelli, FD4 aut
700a Sanders, G4 aut
700a Berrisford, R4 aut
700a Harden, C4 aut
700a Lewis, M4 aut
700a Cheong, E4 aut
700a Kumar, B4 aut
700a Parsons, SL4 aut
700a Soomro, I4 aut
700a Kaye, P4 aut
700a Saunders, J4 aut
700a Lovat, L4 aut
700a Haidry, R4 aut
700a Igali, L4 aut
700a Scott, M4 aut
700a Sothi, S4 aut
700a Suortamo, S4 aut
700a Lishman, S4 aut
700a Hanna, GB4 aut
700a Moorthy, K4 aut
700a Peters, CJ4 aut
700a Grabowska, A4 aut
700a Coleman, H4 aut
710a Karolinska Institutet4 org
773t Gutd : BMJg 68:11, s. 1918-1927q 68:11<1918-1927x 1468-3288x 0017-5749
856u https://gut.bmj.com/content/gutjnl/68/11/1918.full.pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:142430259
8564 8u https://doi.org/10.1136/gutjnl-2018-317624

Hitta via bibliotek

  • Gut (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy